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Abstract
Background: Adherence to osteoporosis pharmacotherapy is poor, and linked with patient
perceptions of the benefits of, and barriers to taking these treatments. To better understand the
association between patient perceptions and osteoporosis pharmacotherapy, we generated
thirteen items that may tap into patient perceptions about the benefits of, and barriers to
osteoporosis treatment; and included these items as part of a standardized telephone interview of
women aged 65–90 years (n = 871). The purpose of this paper is to report the psychometric
evaluation of our scale.
Findings: Upon detailed analysis, six of the thirteen items were omitted: four redundant, one did
not correlate well with any other item and one factorial complex. From the remaining seven items,
two distinct unidimensional domains emerged (variance explained = 78%). Internal consistency of
the 5-item osteoporosis drug treatment benefits domain was good (Cronbach's alpha = 0.88), and
was supported by construct validity; women reporting a physician-diagnosis or taking osteoporosis
pharmacotherapy had higher osteoporosis treatment benefit scores compared to those reporting
no osteoporosis diagnosis or treatment respectively. Because only two items were identified as
tapping into treatment barriers, we recommend they each be used as a separate item assessing
potential barriers to adherence to osteoporosis pharmacotherapy, rather than combined into a
single scale.
Conclusion: The 5-item osteoporosis drug treatment benefits scale may be useful to examine
perceptions about the benefits of osteoporosis pharmacotherapy. Further research is needed to
develop scales that adequately measure perceived barriers to osteoporosis pharmacotherapy.
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Background
Osteoporosis is a major public health problem resulting
in considerable fracture-related morbidity [1,2]. Current
therapies for osteoporosis maintain or improve bone den-
sity by affecting bone remodelling, and thereby reduce
fracture risk [3]. However, rates of prescribing among
those who would benefit, and adherence to therapy in
those prescribed, are suboptimal. For example, fewer than
half of fracture patients are treated to reduce the risk of
recurrent fractures, and of those who initiate osteoporosis
pharmacotherapy, more than 40% discontinue treatment
within the year following initiation [4,5]. The Health
Belief Model hypothesizes that individuals will not seek
preventive care unless they perceive disease to be threaten-
ing, believe that health maintenance is efficacious (bene-
fits), find barriers to care minimal, and receive cues to
action [6]. Based on this model, a patient at high risk for
fracture would not begin treatment, or adhere to pharma-
cotherapy, unless they believe the benefits of treatment
outweigh its barriers. Consistent with this model, we
recently found that patient perceptions of the benefits of
pharmacotherapy were independently correlated with
osteoporosis treatment [7]. The purpose of this paper is to
report our psychometric evaluation of the scale used to
examine patient perceptions of osteoporosis treatment
benefits and barriers, so that others may benefit from our
experience in scale development, and to facilitate future
research examining patient perceptions about osteoporo-
sis pharmacotherapy.
Methods
Details of study recruitment have been previously pub-
lished [8,9]. In brief, we sampled 1,500 women (750 from
each of two regions) from a list of residents who had com-
pleted a short screener questionnaire about arthritis [10],
for a new study focused on osteoporosis management.
Community-dwelling women aged 65–90 years, residing
within the two sampled regions, and able to complete the
telephone interview were eligible. Data collection was
completed by standardized telephone interview in 2003
and 2004. The questionnaire included thirteen items that
we generated to measure patient perceptions about the
benefits of, and barriers to osteoporosis pharmacother-
apy. We generated the thirteen items using a similar for-
mat (item wording and response structure) to the
Osteoporosis Health Beliefs Scale, that was also included
as part of the standardized interview. The Osteoporosis
Health Beliefs Scale was developed based on the Health
Belief Model to measure six osteoporosis-related health
beliefs: susceptibility, severity, exercise benefits, exercise
barriers, calcium benefits and calcium barriers; and gen-
eral health motivation [11,12]. Each item has a 5-point
response option from strongly disagree to strongly agree.
In generating our thirteen items, we were careful to
include questions about "osteoporosis" separately from
"broken bones" to differentiate between respondents who
understand that osteoporosis is about brittle bones, from
those who may not (e.g., confuse osteoporosis with oste-
oarthritis).
Statistical Analysis
Measures of central tendency and response distribution
were summarized for each of the thirteen items generated.
Items to which over 80% of participants either agreed
(strongly agree and agree) or disagreed (strongly disagree
and disagree) were flagged as having poor discriminative
ability [13]. Inter-item correlations were examined using
polychoric correlation coefficients in PRELIS 2.72 (Scien-
tific Software International, Lincolnwood, IL, USA). Pairs
of items with a correlation of 0.90 or higher were consid-
ered redundant. Redundant items do not contribute addi-
tional information to the underlying construct being
measured, yet add to respondent burden. We thus omitted
redundant items to improve the utility of our scale for
future use. After excluding redundant items, scale struc-
ture was evaluated by exploratory factor analysis using
polychoric correlation and asymptotic covariance matri-
ces in LISREL 8.72 (Scientific Software International, Lin-
colnwood, IL, USA). Our goal was to identify distinct
(unidimensional) domains measuring patient percep-
tions about osteoporosis pharmacotherapy. We therefore
excluded complex loading items. Kaiser-Guttman crite-
rion of eigenvalues ≥ 1.0, Cattell's scree plots [14], and
interpretability were used in deciding upon the number of
factors to retain [15]. Factor loadings ≥ 0.4 were consid-
ered important and loadings ≥ 0.5 significant [16]. Final
factor loadings were determined by orthogonal rotation
using the normalized Varimax procedure [17]. The inter-
nal consistency of each domain was tested using Cron-
bach's alpha coefficients [15,18] calculated in SAS 8.02
(SAS, Cary, NC, USA). We calculated summative scores for
each domain that demonstrated adequate internal con-
sistency by adding the responses to each item identified
by factor analysis.
As a sensitivity analysis, we randomly divided our sample
in two, and tested scale structure first using exploratory
factor analysis, and then using confirmatory factor analy-
sis. Given that responses were not normally distributed
across response options, we focused on the standardized
root mean square residual (values < 0.1 being favourable),
and the non-normed fit index (values > 0.9 recom-
mended) in evaluating the performance of scale structure
based on confirmatory factor analysis [16,19].
We tested construct validity of raw domain scores by
hypothesized relationships using unpaired t tests or ANO-
VAs. We specifically hypothesized that osteoporosis drug
treatment benefit scores would be higher among women
reporting physician-diagnosed osteoporosis (versus not)BMC Research Notes 2009, 2:133 http://www.biomedcentral.com/1756-0500/2/133
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and those currently taking osteoporosis pharmacotherapy
(bisphosphonate, calcitonin and/or raloxifene), com-
pared to past use or no osteoporosis drug exposure.
Results
A total of 871 women participated by responding to the
standardized telephone interview (participation rate =
84%, response rate = 72%). The mean and median age of
study participants was 75 years (SD = 6.1). Participants
were similar to nonresponders based on physician-diag-
nosed osteoporosis, fracture history and treatment with
etidronate and hormone therapy, determined by self-
report in 1995 and 1997 [20], Table 1. Participants were
also similar in age (as of May 2003) to women refusing to
participate (mean age = 76 years), but significantly
younger than ineligible women (mean age = 78 years) and
those not contacted (mean age = 77 years).
Table 2 lists the thirteen items generated to assess patient
perceptions about osteoporosis pharmacotherapy, and
summarizes the response distribution for each item. One
item was missing data for one respondent. Two items (8
and 9) had poor discriminative ability with over 80% dis-
agreeing with each statement. Items 2, 4, 5 and 6 were
redundant (polychoric correlations > 0.9) asking similar
questions about "feeling good" or if the participant would
"consider" taking drug treatments to prevent osteoporosis
or broken bones. In an effort to tap both feelings toward
taking drugs to prevent osteoporosis and whether one
would consider pharmacotherapy to prevent fractures,
two of these items (2 and 6) were retained. The Pearson
correlation coefficient between these two items was 0.79
(polychoric correlation coefficient = 0.91). Items 11, 12
and 13 were also redundant, and of the three, item 11 was
retained (based on length and clarity). At the other
extreme, no item correlated well with item 7 (Drug treat-
ment for osteoporosis cost too much); its highest correla-
tion was with item 10 (r = 0.33). This item was therefore
removed from the scale.
After excluding four redundant items (4, 5, 12 and 13)
and item 7 that did not correlate well with any other item,
the remaining eight items were submitted to exploratory
factor analysis resulting in a 2-factor solution. However,
item 10 (Taking drug treatments would upset your every
day routine) demonstrated complex factor loading.
Indeed, weekly bisphosphonates have been available in
Canada since July 2002, calling the generalizability of the
item into question. Therefore, item 10 was removed from
the scale. New evidence has also found that weekly dosing
of bisphosphonates after hip fracture in Pennsylvania
increased from 26% in 2000 (when weekly regimen first
available in the United States), to 100% in 2004 [21].
Subsequent factor analysis resulted in a 2-factor uncorre-
lated solution, Table 3. Domains were labeled based on
the content of their items as: osteoporosis drug treatment
benefits (57% variance explained, 5 items) and drug treat-
ment barriers (21% variance explained, 2 items). Similar
results were observed in sensitivity analyses. Among the
436 randomly allocated to exploratory factor analysis, we
identified the same 2-factor uncorrelated solution (79%
variance explained, 57% benefits and 22% barriers). Scale
structure was further supported by confirmatory factor
analysis among the remaining 435, with standardized
root mean square residual of 0.08, and non-normed fit
index of 0.98.
Internal consistency of the osteoporosis drug treatment
benefits domain was high (Cronbach's alpha = 0.88).
With only 2 items in the barriers domain, the internal
consistency of the scale was low and we do not report the
Cronbach's alpha coefficient. The polychoric correlation
coefficient between the two items was 0.46. In addition,
in terms of face validity, the items appear to tap unrelated
constructs; one taps into subjective impression (too many
Table 1: Characteristics of study responders and non-responders,* N = 1,500
Participant Refused Unable to reach Ineligible
(N = 871) (N = 171) (N = 174)† (N = 284)
n( % ) ‡ n( % ) ‡ n( % ) ‡ n( % ) ‡
Physician-diagnosed osteoporosis 94 (13.1) 16 (11.3) 24 (17.0) 36 (15.0)
Fracture since age 40§ 122 (14.6) 16 (9.8) 11 (6.9) 36 (13.4)
Etidronate use (ever) 12 (1.6) 1 (0.7) 2 (1.5) 8 (3.5)
Hormone therapy
never 552 (68.9) 113 (73.4) 108 (72.5) 187 (73.6)
now 113 (14.1) 25 (16.2) 16 (10.7) 36 (14.2)
past 136 (17.0) 16 (10.4) 25 (16.8) 31 (12.2)
* Based on self-reported data collected between 1995 and 1997 [20].
† Includes 150 for whom we were unable to locate [8], and 14 that we were unable to contact by the end of study recruitment in 2004.
‡ Proportions adjusted for missing data.
§ Wrist, arm, hip, rib, pelvis, or vertebrae; proportions statistically similar except for differences between those "unable to reach," compared to 
participants or ineligible subjects.BMC Research Notes 2009, 2:133 http://www.biomedcentral.com/1756-0500/2/133
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medication), and the other assesses medical contraindica-
tions to therapy/other conditions that affect use of medi-
cations (limited due to stomach problems). For these
collective reasons, construct validity testing was restricted
to the "benefits" domain. As hypothesized, women
reporting to have a physician-diagnosis of osteoporosis
had higher osteoporosis drug treatment benefit scores
compared with those reporting no diagnosis (18.5 vs.
16.6, p < 0.001). Similarly, women taking pharmacother-
apy (bisphosphonates, calcitonin and/or raloxifene) had
higher osteoporosis drug treatment benefits scores: 19.6
for current use compared with 16.5 among past users and
16.4 for never users (p < 0.001). Although some hypoth-
esized differences were small in magnitude, collectively all
of these data (factor analysis, reliability and validity) sug-
gest that the osteoporosis drug treatment benefits scale
measures perceived benefits of osteoporosis drug treat-
ment.
Discussion
Understanding patient perceptions about the benefits of,
and barriers to taking medications may help to under-
Table 2: Univariate statistics for items generated to measure patient perceptions about osteoporosis pharmacotherapy, N = 871
Distribution Response Frequency (%)
Item m e a n S D1234 5
1 Drug treatments can help to build strong bones 3.49 0.66 0.1 8.5 33.6 57.6 0.1
2 You would feel good about taking drug treatments to prevent osteoporosis 3.14 0.91 1.0 31.8 19.9 46.7 0.6
3 Drug treatments can cut down the chances of broken bones 3.45 0.67 0.2 9.2 35.9 54.3 0.3
4 You would feel good about taking drug treatments to prevent broken bones 3.14 0.92 1.3 31.9 19.3 47.0 0.6
5 You would consider taking drug treatments to prevent osteoporosis 3.31 0.88 0.5 26.1 16.3 56.6 0.6
6 You would consider taking drug treatments to prevent broken bones 3.31 0.88 0.5 25.9 16.3 56.7 0.6
7 Drug treatment for osteoporosis cost too much* 2.58 0.59 0.3 46.5 48.3 4.7 0.1
8† You are taking too many* medications 2.17 0.72 10.4 71.3 9.6 8.5 0.1
9† You have stomach problems that limit your ability to take drug treatment 2.13 0.47 0.7 89.9 4.9 4.4 0.1
10‡ Taking drug treatments would upset your every day routine 2.32 0.65 0.5 75.9 14.7 8.7 0.2
11 If your doctor advised you to, you would take drug treatments to prevent broken bones 3.64 0.62 0.2 6.3 23.2 69.5 0.8
12 If your doctor told you that you were at high risk, you would consider taking drug 
treatments to prevent osteoporosis
3.81 0.64 0.3 4.8 15.5 72.6 6.8
13 If your doctor told you that you were at high risk, you would consider taking drug 
treatments to prevent broken bones
3.81 0.64 0.3 4.6 15.8 72.4 6.8
1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree.
* Underlined words may be value-laden or vague.
† Item has poor discriminative ability, i.e., >80% of respondents disagree (disagree or strongly disagree) with the statement.
‡ Data available for 870 participants.
Table 3: Factor loadings for the osteoporosis drug treatment benefits and drug treatment barriers sub-scales, N = 871
Factor Loadings*
Items Benefits Barriers Unique Variance
Osteoporosis drug treatment benefits†
1 Drug treatments can help to build strong bones 0.80 0.07 0.36
2 You would feel good about taking drug treatments to 
prevent osteoporosis
0.94 -0.06 0.11
3 Drug treatments can cut down the chances of broken 
bones
0.87 0.10 0.25
6 You would consider taking drug treatments to prevent 
broken bones
0.90 -0.06 0.17
11 If your doctor advised you to, you would take drug 
treatments to prevent broken bones
0.78 -0.12 0.36
Drug treatment barriers†
8‡ You are taking too many medications -0.12 0.85 0.25
9‡ You have stomach problems that limit your ability to 
take drug treatment
0.14 0.56 0.69
*Varimax solutions calculated using polychoric correlation and asymptotic covariance matrices, explains 78.2% of model variance (benefits: 57.2%, 
barriers: 21.0%).
† Sub-scales labeled based on item content.
‡ Items 8 and 9 reverse coded prior to factor analysis.BMC Research Notes 2009, 2:133 http://www.biomedcentral.com/1756-0500/2/133
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stand why those with clinical need for a preventive agent
may not initiate therapy or do not adhere to long-term
therapy. We generated a number of items to tap different
aspects of osteoporosis drug treatment attitudes and per-
ceptions. These included issues related to costs of treat-
ment, side effects, prevention of broken bones, and the
role of physicians in taking medication. From among
these items, a factor emerged related to perceived benefits
of osteoporosis pharmacotherapy in preventing broken
bones. This factor had good internal consistency and
some preliminary validity suggesting that it may be useful
to include in studies that examine drug treatment adher-
ence and osteoporosis management more generally.
Nonetheless, more research needs to be conducted to
examine whether there are other dimensions that were
not sufficiently captured by the thirteen items that we gen-
erated. The benefits of pharmacotherapy examined in our
scale focused on fracture prevention. Although this is
directly in line with the Health Belief Model [6], suggest-
ing that a woman will not take action unless she believes
it to be efficacious, we cannot comment on whether there
are other benefits that we did not consider or capture. In
particular, we need to learn more about patient percep-
tions regarding the barriers to osteoporosis pharmaco-
therapy. Prior research has documented several potential
barriers to adhering to osteoporosis pharmacotherapy,
including: side effects (e.g., gastrointestinal tolerability),
complexity of dosing regimen, patient safety concerns,
inadequate patient knowledge, lack of noticeable symp-
toms or symptom improvements, patient preferences for
medication use in general, patient-provider communica-
tion, patient involvement in treatment decision making
and adequacy of treatment follow-up [22-24]. Our meth-
odology in generating items is limited by not having
tapped into all of the potential barriers to osteoporosis
pharmacotherapy. Indeed, there are standard methods for
generating items when designing multi-items scales. Dif-
ferent strategies may include one or more of the follow-
ing: conducting focus groups, key informant interviews,
clinical observation, theory, research and expert opinion
[13,25]. Although our items are theory-driven (Health
Belief Model), they do not cover the potential breadth of
barriers to osteoporosis pharmacotherapy. It is therefore
not surprising that we were unable to identify different
domains tapping into specific barriers to osteoporosis
treatment. Being faced with the desire to include patient
perceptions regarding the benefits and barriers to oste-
oporosis pharmacotherapy, and the dilemma of not find-
ing a validated scale at the start of data collection, we
opted to modify existing items from the Osteoporosis
Health Belief Scale. Although this strategy is not a robust
means of creating multi-item scales, by working with a
previously validated scale that examines osteoporosis
health beliefs, we were able to develop a multi-item scale
that measures patient perceptions regarding the benefits
of osteoporosis pharmacotherapy.
Conclusion
The 5-item osteoporosis drug treatment benefits scale has
good psychometric properties among older women and
may be useful in future research studies. However, further
examination of the properties of the scale is recom-
mended, and further work to identify and develop meth-
ods to measure the diverse barriers to osteoporosis
pharmacotherapy is warranted.
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